SCI — Investor Presentation 2025

Feb 13, 2025

2月 13 日 - 2025

SCI PHARMTECH, INC 旭富製藥法人說明會

==> picture [137 x 47] intentionally omitted <==

公司概況 (COMPANY PROFILE)

• 公司概況 (Company Profile)

• ： 271

• 員工數 (Employees)

• 設立日期 (Date of Establishment) ： 1987 年 9 月 18 日

• 資本額 (Capital) ： 新台幣 11.95 億元 (NTD 1,195 million)

• 營業項目 (Business Scope)：

• 原料藥 (API) ： 71.37%

• 中間體 (Intermediate) ： 27.31%

• 其他化學品 (Other Chemicals) ： 1.32%

==> picture [353 x 452] intentionally omitted <==

==> picture [21 x 60] intentionally omitted <==

Y2023 Sales

==> picture [144 x 137] intentionally omitted <==

歐洲 (Europe) 美洲 (America) 亞洲 (Asia) 國內 (Taiwan) 其他 (Other)

Y2024 Sales

==> picture [144 x 138] intentionally omitted <==

歐洲 (Europe) 美洲 (America) 亞洲 (Asia) 國內 (Taiwan) 其他 (Other)

公司概況 (COMPANY OUTLINE)

Sales

==> picture [434 x 246] intentionally omitted <==

----- Start of picture text -----

3.47%
其他 (Other)
2.56%
國內 (Taiwan) 7.99%
9.49%
亞洲 (Asia) 20.48%
12.51%
美洲 (America) 15.24%
13.95%
歐洲 (Europe) 52.82%
61.49%
0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00%
Y2023 Sales Y2024 Sales
----- End of picture text -----

==> picture [22 x 61] intentionally omitted <==

產品組合 (PRODUCTS)

==> picture [871 x 292] intentionally omitted <==

----- Start of picture text -----

5.1% Pent-2 /PEB.Na VA series PGA BZA Dulox.HCl PF.HCl
19.2%
350,000
13.0%
292,718 289,929
300,000 276,917
250,000 232,369
197,954
200,000
15.2% 150,000
19.0% 100,000 77,285
50,000
0
18.2%
Pent-2 VA series PGA BZA Dulox.HCl PF.HCl
Pent-2 /PEB.Na VA series PGA BZA Dulox.HCl PF.HCl
/PEB.Na
----- End of picture text -----

==> picture [21 x 60] intentionally omitted <==

營運概況 (OPERATIONAL OVERVIEW - IS)

==> picture [169 x 476] intentionally omitted <==

Unit: K NTD 營收(Sales) 2024 1,121,889 (Q1~Q3)

營運成本(COGS) 806,068

毛利(Gross Profit) 315,821

毛利率(GP Ratio) 28.2% 營業費用(Operating Expenses) 164,796

營業利益(Operating Income) 151,025 營業外損益(Non-Operating In/Ex) 443,510 稅前淨利(Net Profit before Tax) 594,535 所得稅(Income Tax) 106,687

本期淨利(Net Profit after Tax)

487,848

==> picture [16 x 56] intentionally omitted <==

==> picture [277 x 449] intentionally omitted <==

PENTOBARBITAL SODIUM (PENT-2) 鎮定安眠用中間體及原料藥 Intermediate and API for Calmative

==> picture [520 x 301] intentionally omitted <==

----- Start of picture text -----

350,000
293,838
300,000
292,718
250,000
208,949
200,000
169,670
150,000
153,513
100,000
50,000
0
2020 2021 2022 2023 2024
•K NTD
----- End of picture text -----

==> picture [21 x 60] intentionally omitted <==

==> picture [199 x 197] intentionally omitted <==

==> picture [470 x 236] intentionally omitted <==

----- Start of picture text -----

800,000
717,296
700,000
600,000
500,000
400,000
300,000 303,219
289,929
253,204
200,000
100,000
67,439
0
2020 2021 2022 2023 2024
----- End of picture text -----

==> picture [43 x 10] intentionally omitted <==

----- Start of picture text -----

•K NTD
----- End of picture text -----

VA SERIES: VALPROIC ACID DIVALPROEX SODIUM SODIUM VALPROATE

藥品用途

適應症 Application： 癲癇 (Seizure)躁鬱症 (Bipolar Disorder)、 偏頭痛 (Migraine Headaches)

==> picture [21 x 60] intentionally omitted <==

Pyrogallolaldehyde ( PGA) Benserazide 治療帕金森氏症之中間體

==> picture [18 x 14] intentionally omitted <==

==> picture [66 x 33] intentionally omitted <==

----- Start of picture text -----

301,773
----- End of picture text -----

==> picture [67 x 32] intentionally omitted <==

----- Start of picture text -----

248,153
----- End of picture text -----

==> picture [66 x 33] intentionally omitted <==

----- Start of picture text -----

214,337
----- End of picture text -----

==> picture [66 x 32] intentionally omitted <==

----- Start of picture text -----

313,184
----- End of picture text -----

276,917

Intermediate for Parkinson’s Disease

==> picture [21 x 60] intentionally omitted <==

==> picture [897 x 337] intentionally omitted <==

----- Start of picture text -----

250,000
232,369
200,000
150,000
93,091 100,190
100,000
50,000
52,593 55,017
Brinzolamide
0
青光眼原料藥 2020 2021 2022 2023 2024
API for Glaucoma Medication
•K NTD
----- End of picture text -----

==> picture [21 x 60] intentionally omitted <==

Duloxetine HCl

400,000 364,710 350,000 300,000 250,000 197,954 200,000 150,000 100,000 74,247 65,168 50,000 26,119 0 2020 2021 2022 2023 2024 •K NTD

藥品用途

適應症 Application: 重鬱症(Major Depressive Disorder) 廣泛性焦慮症(Generalized Anxiety Disorder) 糖尿病週邊神經痛(Diabetic Neuropathy) 纖維肌痛(Fibromyalgia) 慢性腰痛(日本地區) Lower Back Pain (only in Japan)

==> picture [21 x 60] intentionally omitted <==

新品項 (New Products)

Buprenorphine & Buprenorphine HCl 止痛劑(Painkiller) 治療鴉片類物質成癮(Opioid Use Disorder) Adenine 糖尿病人傷口癒合 (Diabetic Foot Ulcers Treatment) 血液保鮮劑 (Blood Preservation) Pimobendan 心臟衰竭藥物 (Congestive Heart Failure in Humans and Dogs/Cats) Iron sucrose 缺鐵性貧血 (Iron Deficiency Anemia)

==> picture [16 x 56] intentionally omitted <==

HMTM (to be launched in 2025)

阿茲海默症藥物

(Alzheimer's Disease Medicine)

X project (to P3 clinical trial) 嗜睡和猝倒症 (Narcolepsy)

CDMO Products

N project (launched) 抗癌藥中間體

(Intermediate of API for Oncology Drug)

A projects (P3 clinical trial)

免疫抑制劑中間體

(Intermediates of API for Autoimmune Diseases)

==> picture [16 x 56] intentionally omitted <==

觀音廠&法蘭摩沙 Guanyin Plant and Framosa

==> picture [633 x 319] intentionally omitted <==

預計2025年量產 Both will be commercialized in 2025

==> picture [21 x 60] intentionally omitted <==

No.1 API DMF (USA) CEP (EDQM) ASMF (EMA) KDMF (Korea) MF (Japan) DMF (Canada) CGMP certified (TFDA) GMP certificate (Brazil) China DMF Brazil DMF 1 Adenine 2022 2024 2 Articaine Hydrochloride 2014 2014 2023 2013 2021 3 Allopurinol 2011 2003 2004 4 Atomoxetine Hydrochloride 2018 2018 2016 5 Bisoprolol Fumarate 2006 6 Brinzolamide (082100) 2015 2017 2022(GDP) 2023 6 Brinzolamide (082190) 2024 (082190) 2024 (082190) 2024 (082190) 7 Buprenorphine 2024 2024 8 Buprenorphine Hydrochloride 2024 2024 9 Clindamycin Palmitate HCl 2011 10 DivalproexSodium 2005 2010 2022(GDP) 2023 2010 11 Duloxetine Hydrochloride 2011 2014 2017 2016 2022 (GDP) 2023 2013 12 Hydroxychloroquine Sulfate 2014 2019 2014 2014 2023 2020 13 Loxoprofen Sodium Hydrate 2011 2012 2023 2024 14 MethylphenidateHCl 2014 2022(GDP) 2023 15 PentobarbitalSodium 2011 2022(GDP) 16 Pimobendan 2024 17 Probucol 2004 2017 2015 2022(GDP) 18 Propafenone Hydrochloride 2010 2012 2012 2012 2022 (GDP) 2023 2018 19 Sodium Valproate 2019 2006 2017 2022(GDP) 2023 2014 20 Thiopental 2020 21 Valproic Acid 2003 2004 2008 2008 2022 2023 2023 22 Cannabidiol (CBD) 2020 2020 No.2 API intermediate DMF (USA) CEP (EDQM) MF (Japan) DMF (Canada) CGMP certified (TFDA) 1 Menthadienol (PMDOL) 2019 2 Olivetol 2019 3 Ethyl Olivetolate 2019

==> picture [21 x 60] intentionally omitted <==

THANK YOU FOR LISTENING

==> picture [429 x 540] intentionally omitted <==